Latest Articles
-
Pfizer’s Q2 2015 Earnings Were A Turning Point
Pfizer ‘s (NYSE:PFE) stock saw an uptick following its Q2 2015 financial results which the company announced on July 28th. What we previously expected has been borne out. We had earlier stated that the second quarter results might demonstra...
-
Pfizer Second Quarter Earnings Might Show Some Revival
We believe Pfizer ‘s (NYSE:PFE) Q2 2015 financial results may just show the tipping point for the company’s growth, excluding the impact of currency movements. Pfizer’s profits have been plagued by patent exclusivity losses, cu...
-
Vaccines Are Emerging As Pfizer’s USP
Pfizer (NYSE:PFE) recently announced its decision to acquire two meningitis vaccines, Nimenrix and Mencevax, from GlaxoSmithKline (GSK) for $130 million. Both vaccines are approved for commercial sales and the move builds upon Pfizer’s last...
-
Is Pfizer’s Failure In Anti-Depressant Pristiq Meaningful?
Pfizer (NYSE:PFE) recently met with failure in its study of anti-depressant drug Pristiq in children. The trials did not meet the primary goal of proving that the treatment is more effective than placebo. The market did not react much to this new...
-
Is A Big Acquisition Is Due For Pfizer?
The word on the street is that Pfizer (NYSE:PFE) may attempt another acquisition this year. An analyst from Jefferies believes that it would make more sense for the company to go for a mid-sized acquisition, citing Perrigo and Shire as potential...
-
Pfizer Continues To Strengthen Pipeline With Deals
Pfizer (NYSE:PFE) continues to implement its classic strategy of forming R&D and marketing alliances, and making acquisitions. Recently, it agreed to make an upfront payment of $87.5 million to acquire a stake in Dutch biotech company AM-Phar...
-
Is There A Silver Lining For Pfizer Amid Challenging Conditions?
As expected, Pfizer ‘s (NYSE:PFE) operational growth was overshadowed by adverse currency movements in the first quarter of 2015. However, that’s transient and should not worry investors too much. It is more important to understand w...
-
Pfizer Earnings Preview: Revenue Decline To Continue As Pfizer Searches For New Growth Avenues
Pfizer (NYSE:PFE) expects that much of the decline in revenue for 2015 will be due to the effect of recent and expected product losses of exclusivity. This effect is expected to reduce the company’s revenue by $3.5 billion this year. Its revenues...
-
What Does Recent Biosimilar Approval By The FDA Mean?
In early March, Novartis’ Zarxio became the first biosimilar to be approved in the U.S. by the FDA. A couple of weeks later, Amgen in Federal court was denied in its bid for a preliminary injunction to delay the sale of Zarxio in an attempt...
-
These Three Factors Can Trigger Movement In Pfizer’s Stock Price
Several of Pfizer ‘s (NYSE:PFE) drugs are at a mature stage and thus facing competitive pressure from generics. The company is looking at new avenues for growth, and is certainly not opposed to possibility of large acquisitions, besides sm...
-
Pfizer Can Add 5%-10% Value By Streamlining Its R&D Spending
Pfizer (NYSE:PFE) is known for its financial discipline, but its adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) plummeted by roughly 17% in 2014 despite only 3.8% decline in revenues. This can be attributed to lo...
-
Breaking Down Pfizer’s Acquisition Of Hospira
Earlier this month, Pfizer (NYSE:PFE) announced its $17 billion acquisition of Hospira. The company has been looking at new avenues for growth and its vaccines business and oncology pipeline hold some promise. But given its mammoth size, we beli...
-
Pfizer Revenues Suffer Due To Patent Losses And Currency Headwinds
Pfizer (NYSE:PFE) reported its 2014 fourth quarter results recently. The company’s sales revenue declined 3% for the quarter and 4% for the full year. This was not surprising considering the lack of growth catalysts and a large number of drugs no...
-
Pfizer Earnings Preview: Vaccines & Oncology Will Shine, But The Company Needs More
Pfizer (NYSE:PFE) will report its Q4 2014 earnings on January 27th. We expect the results to reflect the continued pressure on the company’s topline growth, which comes from the loss of patents and the termination of co-promotion agreements...
-
What 2015 Will Bring For Pfizer?
Pfizer ‘s (NYSE:PFE) investors will be hoping for something significant in 2015. The company has been scouting for acquisition candidates in a bid to spur its stunted growth. There are some drugs that are doing well, but a large portion of ...
